Utrophin (UTRN) (UTRN)

Utrophin is a large cytoskeletal protein and an autosomal homolog of dystrophin, sharing approximately 80% sequence homology in key functional domains. In healthy adult muscle, utrophin is primarily restricted to the neuromuscular and myotendinous junctions, where it anchors the actin cytoskeleton to the plasma membrane and facilitates acetylcholine receptor clustering. In patients with Duchenne Muscular Dystrophy (DMD), the absence of dystrophin leads to sarcolemmal instability and progressive muscle degeneration; however, utrophin is naturally upregulated at the sarcolemma as a compensatory response, though its levels are insufficient to prevent pathology. The utrophin upregulation pathway is a therapeutic strategy aimed at pharmacologically or genetically increasing utrophin expression to functionally substitute for dystrophin, thereby stabilizing the muscle fiber membrane. This approach is mutation-independent, making it a potential treatment for all DMD and Becker Muscular Dystrophy (BMD) patients regardless of their specific genetic defect. While several small molecules like ezutromid and recombinant proteins like biglycan have entered clinical and preclinical development, achieving the high levels of sustained upregulation required for significant clinical benefit remains a major challenge.

Other names

Dystrophin-related protein 1DRP1DMDLDRPUbiquitous dystrophin

Transcriptional upregulation of the UTRN gene (specifically the Utrophin A promoter), stabilization of utrophin mRNA by blocking microRNA-mediated repression, and recruitment of utrophin to the sarcolemma to functionally compensate for the absence of dystrophin.